An Update on the Benefits and Risks of Rosuvastatin Therapy

Tóth, Peter P.

doi:10.3810/pgm.2014.03.2736

Cited by 16 publications

(9 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different statins (e.g., atorvastatin and rosuvastatin) vary in their LDL-lowering potency, lipophilicity, reno-protection, and anti-inflammatory effects [13] , [14] . However, whether the difference (hydrophilic and lipophilic) between statins influences their ability to reduce CIN risk is unclear.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, two large randomized control trials (RCTs) demonstrated that rosuvastatin significantly reduced the risk of CIN and improved short term clinical outcomes [11] , [12] . However, not all statins (especially, rosuvastatin and atorvastatin) are equivalent; they vary in several properties, including low-density lipoprotein (LDL) cholesterol lowering potency, lipophilicity, renoprotection, anti-inflammatory effects, and their effects on myocardial function [13] , [14] . Whether these differences significantly influence their effect on preventing CIN remains unknown.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention

Liu

Tan

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

ObjectivesWe prospectively compared the preventive effects of rosuvastatin and atorvastatin on contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI).MethodsWe enrolled 1078 consecutive patients with CKD undergoing elective PCI. Patients in Group 1 (n = 273) received rosuvastatin (10 mg), and those in group 2 (n = 805) received atorvastatin (20 mg). The primary end-point was the development of CIN, defined as an absolute increase in serum creatinine ≥0.5 mg/dL, or an increase ≥25% from baseline within 48–72 h after contrast medium exposure.ResultsCIN was observed in 58 (5.4%) patients. The incidence of CIN was similar in patients pretreated with either rosuvastatin or atorvastatin (5.9% vs. 5.2%, p = 0.684). The same results were also observed when using other definitions of CIN. Clinical and procedural characteristics did not show significant differences between the two groups (p>0.05). Additionally, there were no significant inter-group differences with respect to in-hospital mortality rates (0.4% vs. 1.5%, p = 0.141), or other in-hospital complications. Multivariate logistic regression analysis revealed that rosuvastatin and atorvastatin demonstrated similar efficacies for preventing CIN, after adjusting for potential confounding risk factors (odds ratio = 1.17, 95% confidence interval, 0.62–2.20, p = 0.623). A Kaplan–Meier survival analysis showed that patients taking either rosuvastatin or atorvastatin had similar incidences of all-cause mortality (9.4% vs. 7.1%, respectively; p = 0.290) and major adverse cardiovascular events (29.32% vs. 23.14%, respectively; p = 0.135) during follow-up.ConclusionsRosuvastatin and atorvastatin have similar efficacies for preventing CIN in patients with CKD undergoing PCI.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention

Liu

Tan

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The synthesis of guanidinesh as received considerable attention [9] becauset hese simple nitrogen-containingm olecules are valuableb uilding blocks present in numerousn atural products and pharmaceuticals. [10] Furthermore, they find extensive applications as precursors of ancillary ligands forn umerous transition-,l anthanoid-, and main-group-metal complexes [11] and they can also be employed as organocatalysts. [12] Atom-economical catalytic addition of aminestocarbodiimides (guanylation reaction, Scheme 1) constitutes one of the most straightforwardr outes to accessN -substituted guanidines.…”

Section: Introductionmentioning

confidence: 99%

Structural and Mechanistic Insights into s‐Block Bimetallic Catalysis: Sodium Magnesiate‐Catalyzed Guanylation of Amines

Tullio

Hernán‐Gómez

Livingstone

et al. 2016

Chemistry A European J

View full text Add to dashboard Cite

To advance the catalytic applications of s-block mixed-metal complexes, sodium magnesiate [NaMg(CH SiMe ) ] (1) is reported as an efficient precatalyst for the guanylation of a variety of anilines and secondary amines with carbodiimides. First examples of hydrophosphination of carbodiimides by using a Mg catalyst are also described. The catalytic ability of the mixed-metal system is much greater than that of its homometallic components [NaCH SiMe ] and [Mg(CH SiMe ) ]. Stoichiometric studies suggest that magnesiate amido and guanidinate complexes are intermediates in these catalytic routes. Reactivity and kinetic studies imply that these guanylation reactions occur via (tris)amide intermediates that react with carbodiiimides in insertion steps. The rate law for the guanylation of N,N'-diisopropylcarbodiimide with 4-tert-butylaniline catalyzed by 1 is first order with respect to [amine], [carbodiimide], and [catalyst], and the reaction shows a large kinetic isotopic effect, which is consistent with an amine-assisted rate-determining carbodiimide insertion transition state. Studies to assess the effect of sodium in these transformations denote a secondary role with little involvement in the catalytic cycle.

show abstract

“…It has a longer plasma half-life and stronger antiinflammatory effects than atorvastatin. 17 A recent experimental study performed by Ferreira et al demonstrated that rosuvastatin performed better than atorvastatin or simvastatin through attenuating both inflammation and oxidative stress parameters. 18 In addition, short-term treatment with rosuvastatin may also improve eGFR, independent of lipid fraction changes, supporting the hypothesis that statins might have pleiotropic mechanisms of action that include renal benefits.…”

Section: Discussionmentioning

confidence: 99%

Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization

Yang

2015

Medicine

View full text Add to dashboard Cite

We performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the protective effects of rosuvastatin on contrast-induced acute kidney injury (CI-AKI) and major adverse cardiovascular events (MACEs) in patients undergoing cardiac catherization.PubMed, MEDLINE, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Central RCTs were searched for RCTs from inception to May 2015, to compare rosuvastatin for preventing CI-AKI with placebo treatment in patients undergoing cardiac catherization.Five RCTs with a total of 4045 patients involving 2020 patients pretreated with rosuvastatin and 2025 control patients were identified and analyzed. Patients treated with rosuvastatin had a 51% lower risk of CI-AKI compared with the control group based on a fixed-effect model (OR = 0.49, 95% CI = 0.37–0.66, P < 0.001), and showed a trend toward a reduced risk of MACEs (OR = 0.62, 95% CI = 0.36–1.07, P = 0.08). A subgroup analysis showed that studies with Jadad score ≥3 showed a significant reduction of CI-AKI (OR = 0.53, 95% CI, 0.38–0.73, P < 0.001). However, the risk of CI-AKI did not significantly differ in the studies with Jadad score <3 (OR = 0.54, 95% CI, 0.13–2.24, P = 0.40). In addition, the rosuvastatin treatment showed no effect for preventing CI-AKI in patients with chronic kidney disease (CKD) undergoing elective cardiac catherization (I2 = 0%, OR = 0.81, 95% CI = 0.41–1.61, P = 0.55).This updated meta-analysis demonstrated that preprocedural rosuvastatin treatment could significantly reduce the incidence of CI-AKI, with a trend toward a reduced risk of MACEs in patients undergoing cardiac catheterization. However, rosuvastatin treatment did not seem to be effective for preventing CI-AKI in CKD patients undergoing elective cardiac catheterization.

show abstract

An Update on the Benefits and Risks of Rosuvastatin Therapy

Cited by 16 publications

References 65 publications

Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention

Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention

Structural and Mechanistic Insights into s‐Block Bimetallic Catalysis: Sodium Magnesiate‐Catalyzed Guanylation of Amines

Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization

Contact Info

Product

Resources

About